CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today reported financial results for the first quarter ended March 31, 2009. “Significant recent accomplishments, including the signing of an oncology-focused collaboration with Novartis and the clinical advancement of a CombinatoRx-derived combination product candidate by our ophthalmic collaborator, Fovea, are evidence that the strategy to focus on our core strengths of identifying novel product candidates based on synergy and selectivity is generating interest and creating value from a partnership perspective,” commented Alexis Borisy, President and CEO of CombinatoRx.
